Projects per year
Personal profile
Personal profile
Dr. Abdelrahim completed pharmacy training followed by graduate work in the field of pharmacology and toxicology. Upon completion of his graduate work, clinical training as a medical oncologist fueled his motivation and expertise in the field of anticancer drug discovery.
His translational research is focusing on the discovery and development of new anticancer drugs. He has identified for the first time a new structural class of compounds that can target selective transcription factor called Sp proteins. Transcription factors are now recognized as targets for the development of new anticancer drugs.
Research interests
- Targeted therapy in GI cancer
- Immunotherapy
- T cell therapy
Dr. Abdelrahim's research has pinpointed few compounds that inhibit tumor growth and angiogenesis in-part by inducing proteasome-dependent degradation of selected Sp proteins in cancer cells and tumors. The lead compound of this class (Tolfenamic acid) has reached Phase I Clinical Trial to treat patients with advanced and metastatic pancreatic cancer in combination with gemcitabine and radiation therapy. Dr. Abdelrahim has a patent application submitted for the new use of these compounds in GI cancers. In prior research, he was the first to find that Sp4 protein is over expressed in GI cancers including pancreatic cancer and that the role of Sp4 can be equally important as Sp1 in some type of GI cancers.
Researchers in cancer have the ultimate responsibility of taking their findings to the clinic which is described as translational research. By seeing GI cancer patients in his practice, collaborating with translational scientist in the lab and conducting and directing clinical trials, Dr. Abdelrahim hopes to continue to fuel the translational research cycle from lab to clinic and back to the lab.
Education/Academic qualification
Medicine, MD, Texas A&M Health Science Center College of Medicine
Jul 1 2008 → Jun 30 2012
Award Date: Aug 12 2018
Hematology, Fellow, Duke University Medical Center
Jul 1 2015 → Jun 30 2017
Award Date: Jun 30 2017
Internal Medicine, Residency
Jul 1 2013 → Jun 30 2015
Award Date: Jun 30 2015
Internal Medicine, Internship, Baylor College of Medicine
Jul 1 2012 → Jun 30 2013
Award Date: Jun 30 2013
PhD, Texas A&M University
Sep 1 2000 → May 31 2004
Award Date: May 31 2004
Pharmacy, B Pharm, Isra University
Sep 1 1994 → May 31 1999
Award Date: May 31 1999
External positions
Adjunct Assistant Professor, Texas A&M University
Jul 1 2012 → …Research Area Keywords
- Cancer
- Clinical Translation & Trials
- Clinical Care
Free-text keywords
- Gastrointestinal cancer
- Clinical research
- Clinical trials
- Translation research
Fingerprint
- 4 Similar Profiles
Network
Projects
-
Phase III_NivoIpi_HCC_Check Mate 9DW_CA2099DW BMS
Heyne, K., Abdelrahim, M. & Darcourt, J.
9/24/20 → …
Project: Clinical Trial
-
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
Pingali, S. R., Abdelrahim, M., Bernicker, E. H., Chang, J. C., Darcourt, J., Heyne, K., Niravath, P. A., Petkova, J., Randhawa, J., Rice, L. & Singh, M.
7/8/20 → …
Project: Clinical Trial
-
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
Niravath, P. A., Abdelrahim, M., Arentz, C., Chang, J. C., Darcourt, J., Geyer, C. E., Heyne, K. & Singh, M.
6/16/20 → …
Project: Clinical Trial
-
A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
Singh, M., Abdelrahim, M., Beinart, G. & Heyne, K.
5/18/20 → …
Project: Clinical Trial
-
A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)
Abdelrahim, M., Bernicker, E. H., Chang, J. C., Darcourt, J., Heyne, K., Niravath, P. A., Singh, M. & Zhang, J.
4/27/20 → …
Project: Clinical Trial
Research Output
-
Acquired haemophilia as a paraneoplastic manifestation of pancreatic cancer
Arain, A., Muhsen, I. N. & Abdelrahim, M., Jun 4 2020, In : ecancermedicalscience. 14, 1053.Research output: Contribution to journal › Article
-
Checkpoint inhibitor-related renal vasculitis and use of rituximab
Mamlouk, O., Lin, J. S., Abdelrahim, M., Tchakarov, A. S., Glass, W. F., Selamet, U., Buni, M., Abdel-Wahab, N. & Abudayyeh, A., Jul 1 2020, In : Journal for immunotherapy of cancer. 8, 2Research output: Contribution to journal › Article
1 Scopus citations -
Commentary on Neoadjuvant Versus Surgery First Approach in Resectable Pancreatic Ductal Adenocarcinoma
Saharia, A., Potter, L., Baio, F., Elshawwaf, M., Abdelrahim, M. & Heyne, K., Oct 1 2020, In : American Journal of Clinical Oncology: Cancer Clinical Trials. 43, 10, p. 753-754 2 p.Research output: Contribution to journal › Letter
-
Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer (Cancer Chemotherapy and Pharmacology, (2020), 85, 3, (621-626), 10.1007/s00280-020-04037-9)
Babiker, H. M., Milhem, M., Aisner, J., Edenfield, W., Shepard, D., Savona, M., Iyer, S., Abdelrahim, M., Beach, C. L., Skikne, B., Laille, E., Tsai, K. T. & Ho, T., May 1 2020, In : Cancer Chemotherapy and Pharmacology. 85, 5, p. 1009-1010 2 p.Research output: Contribution to journal › Comment/debate
-
Development and validation of a risk assessment tool for BKPyV Replication in allogeneic stem cell transplant recipients
Abudayyeh, A., Lin, H., Abdelrahim, M., Rondon, G., Andersson, B. S., Martinez, C. S., Page, V. D., Tarrand, J. J., Kontoyiannis, D. P., Marin, D., Oran, B., Olson, A., Jones, R., Popat, U., Champlin, R. E., Chemaly, R. F., Shpall, E. J. & Rezvani, K., Oct 1 2020, In : Transplant Infectious Disease. 22, 5, e13395.Research output: Contribution to journal › Article